ALVIO — Valerio Therapeutics SA Share News
0.000.00%
Last trade - 00:00- €195.03m
- €201.58m
- €2.57m
Brief: Valerio Therapeutics Signs Development Collaboration With Abivax
Brief: Valerio Therapeutics Enters Into Collaboration & Exclusive License With Seed-Stage Biotech Co
Brief: Onxeo Changes Its Name And Becomes Valerio Therapeutics
Brief: Onxeo H1 Net Loss Widens To EUR 11.5 Mln
Brief: Onxeo Announces That Nasdaq Approved The Delisting Of Its Shares From The First North Growth Market In Copenhagen
Brief: Initial Ind Application For Asidna Granted “Study May Proceed” By The U.S. FDA
Brief: Onxeo Appoints Dr. Shefali Agarwal As CEO
Brief: Onxeo End-December Cash Position At EUR 17.9 Million
Brief: Onxeo To Present New Preclinical Data Highlighting Asidna’s Ability To Fight Tumor Resistance
Brief: Onxeo Says New Data Confirms Relevance Of Combining AsiDNA™ With PARPi In HRP Tumor Models
Brief: Onxeo Appoints Julien Miara As Interim CEO
Brief: Onxeo Says New Preclinical Data Confirm Antitumoral Properties Of AsiDNA
Brief: Onxeo Announces The Appointment Of Dr. Shefali Agarwal As The Company’S Chairwoman Of The Board
Brief: Onxeo Net Result Turns To Loss Of EUR 4.8 Mln
Brief: Onxeo Receives Notice Of Allowance For New Patent
Brief: Onxeo Announces Formation Of Scientific Advisory Committee
Brief: Onxeo To Present New Preclinical Data At AACR 2021
Brief: Onxeo Launches Capital Increase Of Target Eur 9.3 Mln
Brief: Onxeo Enters Clinical Research Agreement With Institut Curie